Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
MeiraGTx is a clinical-stage gene therapy company developing treatments for inherited retinal diseases, neurodegenerative disorders, and salivary gland diseases using adeno-associated virus (AAV) vectors. The company has multiple programs in clinical trials including botaretigene sparoparvovec for X-linked retinitis pigmentosa (XLRP) and AAV-CNGB3 for achromatopsia, with potential near-term regulatory milestones. Stock performance is driven by clinical trial readouts, regulatory decisions, partnership announcements, and cash runway visibility given the pre-revenue burn rate of approximately $100M annually.
MeiraGTx operates a classic biotech development model: invest heavily in R&D to advance gene therapy candidates through clinical trials, then monetize through either direct commercialization of approved products or out-licensing to larger pharmaceutical partners. The company's proprietary AAV manufacturing capabilities and ocular gene therapy expertise provide differentiation. Current 28.5% gross margin reflects manufacturing service revenue, but future approved therapies could command premium pricing given orphan drug status and one-time curative treatment paradigm. The business model requires sustained capital raises until product approval and commercialization generate positive cash flow, likely 2027-2028 at earliest for lead programs.
Clinical trial data readouts for botaretigene sparoparvovec (XLRP program) and AAV-CNGB3 (achromatopsia program)
FDA regulatory decisions including Biologics License Application (BLA) submissions and approvals
Partnership announcements or expansions with pharmaceutical companies providing validation and non-dilutive funding
Cash runway updates and equity financing announcements given 0.22x current ratio and negative operating cash flow
Competitive developments in ocular gene therapy space from Spark Therapeutics, Biogen, and other AAV platform companies
Gene therapy safety concerns following industry-wide adverse events could trigger regulatory scrutiny and slow approval timelines across all AAV-based programs
Manufacturing complexity and scalability challenges for AAV vectors with limited contract manufacturing options and high cost-of-goods that may not support commercial viability
Reimbursement uncertainty for high-cost one-time gene therapies with payers increasingly resistant to multi-million dollar treatments despite curative potential
Competitive ocular gene therapy programs from better-capitalized companies like Biogen, Roche, and Novartis targeting overlapping indications with potentially faster development timelines
Alternative treatment modalities including CRISPR gene editing, RNA therapies, and small molecules that could obviate need for AAV gene therapy approaches
Critical liquidity risk with 0.22x current ratio and negative $100M operating cash flow requiring near-term capital raise that will be highly dilutive at current $600M market cap
Negative equity position implied by -15.2x price-to-book suggests accumulated deficit exceeds assets, limiting financial flexibility and increasing dependence on equity markets
No debt cushion (negative D/E) means inability to access non-dilutive debt financing, forcing reliance on equity raises in potentially unfavorable market conditions
low - Pre-revenue biotech companies are largely insulated from GDP fluctuations as they have no commercial sales exposed to consumer spending or business investment cycles. However, severe recessions can impact ability to raise capital and valuations of unprofitable growth companies. The rare disease focus further reduces economic sensitivity as treatments address critical medical needs regardless of economic conditions.
High sensitivity through multiple channels: (1) Valuation impact - biotech stocks trade on discounted future cash flows, so rising rates compress NPV of projected revenues 5-10 years out, (2) Financing costs - while current debt is minimal (negative D/E suggests equity-financed), future capital raises become more expensive in high-rate environments as investors demand higher returns, (3) Opportunity cost - rising risk-free rates make speculative pre-revenue biotechs less attractive versus bonds. The 10-year Treasury yield directly impacts discount rates used in DCF models for long-duration assets.
Minimal direct credit exposure as the company is pre-revenue with limited commercial counterparty risk. However, credit market conditions significantly affect ability to access capital markets for equity financing. Widening high-yield spreads signal risk-off sentiment that makes it harder and more dilutive to raise funds needed to sustain $100M+ annual burn rate. Tight credit conditions could force unfavorable partnership terms or asset sales.
growth - Attracts speculative biotech investors willing to accept binary clinical/regulatory risk for potential multi-bagger returns if gene therapies gain approval. The pre-revenue profile, negative margins, and clinical-stage pipeline appeal to high-risk tolerance growth investors, not value or income investors. Typical holders include biotech-focused hedge funds, venture capital crossover funds, and retail investors seeking lottery-ticket exposure to gene therapy upside.
high - Clinical-stage biotechs exhibit extreme volatility with 50%+ single-day moves common around trial readouts and regulatory decisions. Small $600M market cap amplifies volatility from modest trading volume. The 11.8% one-year return masks significant intra-year swings. Beta likely exceeds 1.5x relative to broader market given speculative nature and binary event risk.
